https://orcid.org/0000-0001-9837-9669
Figures
Abstract
Introduction
Despite the prevalent use of antenatal corticosteroids (ACS) to prevent preterm infants’ adverse neonatal complications, there is currently no consensus on administration-to-birth intervals of ACS. International guidelines broadly agree that the administration of antenatal corticosteroids should be within 7 days prior to preterm birth. However, there is little evidence to support narrower optimal ACS administration-to-birth interval time. This study was undertaken to investigate the association between the administration-to-birth interval of ACS which is bounded by 48 hours and neonatal outcomes in very preterm infants.
Materials and methods
This is a single-center prospective observational study. Data were collected prospectively from eligible infants from January 2008 to April 2014 at the Santa Clara Valley Medical Center, neonatal outcomes were compared between two groups based on the interval of antenatal corticosteroid administration-to-birth: the interval of <48h, and the interval of >48h. It was noted that the entire study was completed by Dongli Song et al., and uploaded the data to the DATADRYAD website. The author only used this data for secondary analysis.
Results
After adjusting potential confounders (gestational age, sex, birth weight, duration of cord clamping and delivery mode), the interval of >48h group compared to the interval of <48h group had significant reductions in mortality (OR: 0.17; 95% CI: 0.05–0.59), any retinopathy of prematurity (OR: 0.36; 95% CI: 0.16–0.82), severe retinopathy of prematurity (OR: 0.07; 95% CI: 0.01–0.45), any intubation (OR: 0.39; 95% CI: 0.20–0.75) and higher 1 min Apgar (β: 0.56; 95% CI: 0.10–1.02).
Citation: Wang D, Ming L, Zhu Y (2023) Antenatal corticosteroid administration-to-birth interval and neonatal outcomes in very preterm infants: A secondary analysis based on a prospective cohort study. PLoS ONE 18(2): e0281509. https://doi.org/10.1371/journal.pone.0281509
Editor: Ahmed Mohamed Maged, Kasr Alainy Medical School, Cairo University, EGYPT
Received: October 13, 2022; Accepted: January 24, 2023; Published: February 10, 2023
Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All data files are available from Dryad at DOI: 10.5061/dryad.4q3d3 (https://doi.org/10.5061/dryad.4q3d3).
Funding: The authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Preterm birth is a worldwide epidemic with a global incidence of 15 million every year [1], while rates of preterm birth in the United States have decreased over the last decade, nearly one out of every ten infants is stillborn preterm [2]. Premature infants are more likely to suffer from respiratory distress syndrome, sepsis, intraventricular hemorrhage (IVH), and necrotizing enterocolitis (NEC) shortly after birth [3, 4], preterm infants also face long-term problems including neurodevelopmental delay, retinopathy of prematurity (ROP), chronic lung disease (CLD) and metabolic dysfunction [5, 6].
Antenatal corticosteroids (ACS) has been widely accepted as the standard for managing pregnancies at risk for preterm delivery, and the impact of ACS on reducing the morbidity and mortality of preterm infants has revolutionized perinatal medicine [7]. In preterm infants, ACS have been shown to significantly reduce the risk of adverse complications, including neonatal death, respiratory distress syndrome, IVH, and sepsis, when corticosteroids are given to pregnant women with a higher likelihood of preterm labor before 34 weeks of gestation [8, 9]. Furthermore, there is no evidence that ACS increases the risk of chorioamnionitis, endometritis, or maternal death [9].
Despite the widespread use of ACS to prevent adverse neonatal complications in preterm infants, and several national and international clinical practice guidelines also make recommendations for initial prenatal corticosteroid administration, there is currently no consensus as to the type of corticosteroid to use, the dose and frequency of use, the timing of use and the route of administration [10–14]. International guidelines broadly agree that the administration of antenatal corticosteroids should be within 7 days prior to preterm birth. However, there have been very few studies investigating the interval time within 7 days between ACS administration to birth, and the results of these studies are inconsistent [15–17].
Based on data that has already been published, we conducted a secondary data analysis for this study [18]. The administration-to-birth interval of ACS was used as an independent variable, and the outcome variables and other covariates are consistent with those in the original study. Aim to investigate the association between the administration-to-birth interval of ACS which is bounded by 48 hours and neonatal outcomes in very preterm infants.
Materials and methods
Data source
We obtained data from the ‘DATADRYAD’ database (www.Datadryad.org). This website permitted users to freely download the raw data. According to Dryad’s Terms of Service, we cited the Dryad data package in the present study. (Dryad data package: Dongli Song; Jegatheesan, Priya; DeSandre, Glenn; Govindaswami, Balaji (2016), Data from Duration of cord clamping and neonatal outcomes in very preterm infants, Dryad, Dataset, https://doi.org/10.5061/dryad.4q3d3). Variables included in the database file were as follows: birth weight, gestational age (GA), duration of cord clamping(duration of time for the neonate at birth before clamping the umbilical cord), multiple pregnancies, the administration-to-birth interval of ACS (time interval from first ACS dose to delivery, ACS in this study refers to complete and incomplete course of medication, because of the high collinearity between number of doses and the interval of ACS, information of one or more doses was not included, as in previous similar studies), delivery mode (cesarean or vaginal delivery), Apgars at 1 and 5 minutes, delivery room (DR) intubation and positive pressure ventilation, DR chest compression and medications, admission temperature (temperature on NICU admission in Celsius), hypothermia (<36 degree Celsius on admission), hematocrit in the first 2 hours of life, hematocrit between 12–36 hours of life, surfactant administration, pneumothorax, intubation <24hr (intubation within 24 hours of life), any intubation (defined as at least once during NICU stay), any red blood cell transfusion (any red blood cell transfusion during the NICU stay), peak bilirubin (mg/dl), death (death before discharge home), any IVH (any grade of intraventricular hemorrhage, grade 1–4), severe IVH (grade 3 or 4, defined as IVH with ventricular dilatation or parenchymal hemorrhage), late onset sepsis (LOS, the age of onset and timing of the sepsis episode >72 h of life), any ROP (any stage of retinopathy of prematurity, stage 1–5), severe ROP (defined as ≥stage 3 or with Plus disease or requiring surgery or anti-vascular endothelial growth factor treatment for ROP.), NEC, CLD, survival without major morbidity (defined as survival without severe IVH, NEC, CLD, Late Onset Sepsis, or severe ROP).
Study population
Dongli Song, et al. [18] completed the entire study. We outline the research steps below to provide a clearer understanding of the entire study process. This observational study was conducted from January 2008 to April 2014 at the Santa Clara Valley Medical Center (SCVMC), a safety-net teaching hospital with a high-risk obstetric service and a regional level III Neonatal Intensive Care Unit (NICU). Data were collected prospectively from January 2008. The study included 353 very preterm infants born at < 32 weeks gestation. Exclusion standards: obstetric causes (placental or cord causes, i.e. placental abruption, placenta previa, cord evulsion, and true knot) and fetal or neonatal causes (i.e. severely compromised infant without spontaneous respiration requiring immediate resuscitation after birth). NICU criteria for DR resuscitation, intubation, surfactant therapy, and transfusion and the target oxygen saturation range for preterm infants did not change during the study period. Demographic characteristics, delivery room /NICU practices, neonatal mortality, and morbidities were collected. This original study was approved by the SCVMC institutional review board as a quality improvement project and informed consent was waived.
Our study divided participants into two groups based on the interval of ACS admission: the interval of ACS>48h and the interval of ACS<48h. A total of 10 participants did not use antenatal steroids, and 343 very preterm infants born at < 32 weeks gestation age were included in this study, subgroup study was conducted on extremely preterm infants with gestation age < 28 weeks.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation, and categorical variables were expressed in frequency or as a percentage. The One-Way ANOVA (normal distribution), Kruskal Wallis H (skewed distribution) test and chi-square tests (categorical variables) were used to determine any statistical differences between the means and proportions of the groups. Fisher Exact for categorical variables with Expects<10. Multivariate logistic regression analysis was used to analyze the significant results between groups, both non-adjusted and multivariate-adjusted models were listed in the paper. According to the recommendation of the STROBE statement, we simultaneously showed the results of unadjusted, minimally adjusted analyses and those fully adjusted analyses. Adjusted covariates include gestational age, sex, birth weight, Duration of Cord Clamping (DCC) group (the 30-45s DCC group and the 60-75s DCC group), and delivery mode. Due to the small proportion of missing values, cases with missing data were deleted during the analysis. All of the analyses were performed with the statistical software packages R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA). P values less than 0.05 (two-sided) were considered statistically significant.
Results
Demographic characteristics of participants
343 very preterm infants born at < 32 weeks gestation age were included in this study. The average gestational age of the participants was 29.7±2.6 weeks, and approximately 38.8% of them were female. Multiple pregnancies accounted for 19.8% of the study participants and cesarean section accounted for 61.2%. Demographics of the study patients are shown in Table 1. There were no significant differences between the two intervals of ACS groups of preterm infants. Of all participants, 2 of them had a lack of peak bilirubin, 16 had a lack of any ROP and severe ROP, and 17 had a lack of CLD outcome.
Univariate analysis
We compared the differences in the interval of ACS and neonatal outcomes between preterm infants at <32 weeks and <28 weeks of gestational age. The results of the univariate analysis are shown in Table 2. About the delivery Room Measures, in the GA <32 weeks group, the 1 min Apgar was higher in the interval of the ACS>48h group than in the interval of the ACS<48h group (6.2±2.1 vs. 5.7±2.4). Likewise, in the GA <28 weeks (extremely preterm birth) subgroup, the 5 min Apgar score was significantly higher in the interval of ACS>48h group (6.9±1.7 vs. 6.1±2.0). And any red blood cell infusion during hospitalization at the NICU was significantly lower (92.3% vs. 70.8%). Other DR and NICU measurements did not differ between the two ACS groups.
In terms of neonatal mortality, compared with the interval of the ACS<48h group, the interval of the ACS>48h group had significantly lower mortality (9.5% vs. 2.1%). A similar reduction was observed in the <28-week GA subgroup (26.9% vs. 7.7%). Regarding neonatal morbidity, any IVH, severe IVH, and severe ROP were significantly lower in the interval of ACS>48h group. A similar reduction was observed in the < 28-week GA subgroup except for any IVH, in addition, in the < 28-week GA subgroup, the mortality of severe ROP also decreased significantly in the interval of ACS>48h group. There were no differences in survival without major morbidity, CLD, LOS, and NEC between the two ACS groups.
The relationship between the interval of ACS and neonatal outcomes
As shown in Table 3, after adjusting for GA, sex, birth weight, DCC group, delivery mode, multivariate logistic regression revealed that five candidate factors remained significant: the observed mortality (OR = 0.17; 95%CI = 0.05–0.59), any ROP (OR = 0.36; 95% CI = 0.16–0.82), severe ROP (OR = 0.07; 95% CI = 0.01–0.45), 1 min Apgar (β = 0.56; 95% CI = 0.10–1.02) and any intubation (OR = 0.39; 95% CI = 0.20–0.75). In the <28-week GA subgroup, significant reductions in mortality (OR = 0.20; 95% CI = 0.04–0.95) and severe ROP (OR = 0.06; 95% CI = 0.01–0.58) were also observed after risk adjustment. There were no statistically significant differences in any ROP, 1min Apgar, and intubation in the GA<28 weeks subgroup after final adjustments.
Discussion
The administration of ACS to reduce morbidity and mortality in newborns at risk of preterm birth before 34–35 weeks of gestational age has been widely accepted and it is now firmly established by guidelines across the world as an evidence-based suggestion [9, 13, 19]. Although fetal lung maturation is generally seen as the primary benefit of ACS treatment, it has also been linked to additional advantages in preterm infants.
In the present study, we found a clear association between the interval of ACS and survival in very preterm infants, the mortality of very preterm infants with an interval of ACS>48h was significantly decreased compared with those with the interval of ACS<48h, as well as in extremely preterm birth. We also found that infants receiving the interval of ACS>48h required less respiratory intervention, had higher 1min Apgar and had a significantly lower risk of ROP.
According to most international guideline recommendations, prenatal corticosteroids should be administered within seven days before a premature birth [13, 19, 20]. However, there is little evidence to support narrower optimal ACS administration-to-birth interval time. Some animal experiments have shown that ACS administration > 48 hours before delivery shows greater benefits in surfactant production than 24 hours before delivery [21, 22], and some vitro studies suggested that the effects of dexamethasone on surfactant protein B gene transcription were maximal at 48 hours of the initial exposure [23, 24]. In a twin pregnancy study, It was only when the ACS delivery interval was between 2 and 7 days that the ACS was associated with a lower risk of RDS [25]. Likewise, Gulersen M found that the adverse outcomes were more common in those born with the ACS interval less than 2 days than in those born with the ACS interval 2–7 days [26]. Antenatal corticosteroids may have positive benefits as early as 3 hours after administration, with their greatest mortality-reducing effects occurring 18 to 36 hours later, according to recent data from the Effective Perinatal Care in Europe cohort research, in addition, 48 hours to 1-week interval of ACS was associated with a significantly lower incidence of serious neonatal brain injury (defined as an intraventricular hemorrhage grade of 3 or 4) [27].
In terms of neonatal mortality, our results are consistent with these findings, in addition, due to the beneficial effects of ACS on the respiratory and cardiovascular systems [10, 28], higher 1 min Apgar scores and lower any intubation rates were found in the potentially better ACS interval group, but for chronic lung disease, there was no significant difference between the two groups.
An important finding in our study was that the interval of ACS>48 hours was associated with a significant reduction in ROP, at present, there is a lack of studies focusing on the interval of ACS and ROP in preterm infants. The retina of a full-term infant is nearly complete at delivery, but the retina of a premature infant is immature at birth [29], the incidence of ROP has strongly connected to gestational age and birth weight, with preterm infants born with low gestational age or birth weight having a higher incidence of ROP [30], our study showed that the association remained significant after adjusting for these factors. Some studies have shown that infants born extremely preterm and with very low birth weight have a decreased risk of severe ROP after ACS [31, 32]. However, a recent meta-analysis suggests that ACS treatment may decrease, but not prevent, the severity of ROP [33]. At present, the evidence of the effect of ACS on ROP is based on some retrospective studies, and more rigorously designed RCT experiments are needed to improve the level of evidence. Meanwhile, our study is a single-center observational study with a relatively limited sample size and the results need to be interpreted with caution. The RCT studies with a larger sample are required to identify the GA-dependent optimal interval of ACS.
Our study is a secondary study of the effect of ACS interval on neonatal outcomes in preterm infants, the interval of ACS was prospectively collected, and the sample size was adequate for analyses that adjusted for mortality and neonatal outcomes according to the interval of ACS and a number of potential confounding variables, and the results were stable and relevant to the management of pregnancies at risk for preterm delivery. However, it has limitations as a single center observational study. First, the original study did not include severely compromised infants who did not have spontaneous respiration and needed resuscitation immediately, some of these preterm infants were already treated for ACS, so the exclusion may have introduced some bias. Second, this observational study itself includes unavoidable possible confounding elements, so in order to reduce these biases, we strictly apply statistical correction to reduce residual confounding. Third, due to raw data limitations, we can not obtain the specific time interval of prenatal exposure to ACS, so the group with ACS > 48 hours was mixed with people with ACS>1 week, some cohort studies have found that increased mortality and adverse outcomes with an ACS administration-to-birth interval exceeding 7 days [17, 27, 34–36], therefore, our conclusions do not apply to preterm infants with ACS > 1 week, after removing these confounders, a stronger association between the interval of ACS>48h and beneficial neonatal outcomes may be found. In view of the fact that this study is a single-center non-RCT study with relatively unitary demographic characteristics, the study has some limitations, moreover, other and unknown differences in case-mix between the different ACS intervals may have occurred, it may be not generalizable to other biographic ethnic groups.
In conclusion, this study shows that in very preterm infants, compared with the interval of ACS<48h, the interval of ACS>48 hours has a significant health promotion effect, this finding is important for clinicians when managing very preterm infants, which may help reduce infant mortality and retinopathy of prematurity.
Acknowledgments
We grateful to the data providers of the study. They completed the entire study. They are Dongli Song (corresponding author), Priya Jegatheesan, Glenn DeSandre, Balaji Govindaswami. The institutions of these authors: Department of Pediatrics, Division of Neonatology, Santa Clara Valley Medical Center, San Jose, California, United States of America.
References
- 1. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2019;7(1):e37–e46. Epub 2019-01-01. pmid:30389451.
- 2. Martin JA, Hamilton BE, Osterman M, Driscoll AK. Births: Final Data for 2019. Natl Vital Stat Rep. 2021;70(2):1–51. Epub 2021-04-01. pmid:33814033.
- 3. Purisch SE, Gyamfi-Bannerman C. Epidemiology of preterm birth. Semin Perinatol. 2017;41(7):387–391. Epub 2017-11-01. pmid:28865982.
- 4. Platt MJ. Outcomes in preterm infants. Public Health. 2014;128(5):399–403. Epub 2014-05-01. pmid:24794180.
- 5. Spittle AJ, Thompson DK, Olsen JE, Kwong A, Treyvaud K. Predictors of long-term neurodevelopmental outcomes of children born extremely preterm. Semin Perinatol. 2021;45(8):151482. Epub 2021-12-01. pmid:34456065.
- 6. Johnson S, Marlow N. Early and long-term outcome of infants born extremely preterm. Arch Dis Child. 2017;102(1):97–102. Epub 2017-01-01. pmid:27512082.
- 7. Thevathasan I, Said JM. Controversies in antenatal corticosteroid treatment. Prenat Diagn. 2020;40(9):1138–1149. Epub 2020-08-01. pmid:32157719.
- 8. Htun ZT, Hairston JC, Gyamfi-Bannerman C, Marasch J, Duarte RA. Antenatal Corticosteroids: Extending the Practice for Late-Preterm and Scheduled Early-Term Deliveries? Children (Basel). 2021;8(4)Epub 2021-04-01. pmid:33916116.
- 9. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12:CD004454. Epub 2020-12-25. pmid:33368142.
- 10. Williams MJ, Ramson JA, Brownfoot FC. Different corticosteroids and regimens for accelerating fetal lung maturation for babies at risk of preterm birth. Cochrane Database Syst Rev. 2022;8:CD006764. Epub 2022-08-09. pmid:35943347.
- 11.
WHO Recommendations on Interventions to Improve Preterm Birth Outcomes. Geneva: World Health Organization. 2015.
- 12.
UK NCCF. Preterm Labour and Birth. London: National Institute for Health and Care Excellence (UK). 2015.
- 13. Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017;130(2):e102–e109. Epub 2017-08-01. pmid:28742678.
- 14. Crane J, Armson A, Brunner M, De La Ronde S, Farine D, Keenan-Lindsay L, et al. RETIRED: Antenatal corticosteroid therapy for fetal maturation. J Obstet Gynaecol Can. 2003;25(1):45–52. Epub 2003-01-01. pmid:12548324.
- 15. Haas DM, McCullough W, McNamara MF, Olsen C. The first 48 hours: Comparing 12-hour and 24-hour betamethasone dosing when preterm deliveries occur rapidly. J Matern Fetal Neonatal Med. 2006;19(6):365–9. Epub 2006-06-01. pmid:16801314.
- 16. Norman M, Piedvache A, Borch K, Huusom LD, Bonamy AE, Howell EA, et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort. Jama Pediatr. 2017;171(7):678–686. Epub 2017-07-01. pmid:28505223.
- 17. Norberg H, Kowalski J, Marsal K, Norman M. Timing of antenatal corticosteroid administration and survival in extremely preterm infants: a national population-based cohort study. BJOG. 2017;124(10):1567–1574. Epub 2017-09-01. pmid:28294496.
- 18. Song D, Jegatheesan P, DeSandre G, Govindaswami B. Duration of Cord Clamping and Neonatal Outcomes in Very Preterm Infants. Plos One. 2015;10(9):e0138829. Epub 2015-01-20. pmid:26390401.
- 19.
Preterm labour and birth. London: National Institute for Health and Care Excellence (NICE). 2019.
- 20. Skoll A, Boutin A, Bujold E, Burrows J, Crane J, Geary M, et al. No. 364-Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes. J Obstet Gynaecol Can. 2018;40(9):1219–1239. Epub 2018-09-01. pmid:30268316.
- 21. Ikegami M, Polk D, Jobe A. Minimum interval from fetal betamethasone treatment to postnatal lung responses in preterm lambs. Am J Obstet Gynecol. 1996;174(5):1408–13. Epub 1996-05-01. pmid:9065104.
- 22. Kemp MW, Saito M, Schmidt AF, Usuda H, Watanabe S, Sato S, et al. The duration of fetal antenatal steroid exposure determines the durability of preterm ovine lung maturation. Am J Obstet Gynecol. 2020;222(2):183.e1–183.e9. Epub 2020-02-01. pmid:31494126.
- 23. Vidaeff AC, Ramin SM, Gilstrap LR, Alcorn JL. Characterization of corticosteroid redosing in an in vitro cell line model. Am J Obstet Gynecol. 2004;191(4):1403–8. Epub 2004-10-01. pmid:15507973.
- 24. Vidaeff AC, Ramin SM, Gilstrap LR, Alcorn JL. In vitro quantification of dexamethasone-induced surfactant protein B expression in human lung cells. J Matern Fetal Neonatal Med. 2004;15(3):155–9. Epub 2004-03-01. pmid:15280140.
- 25. Kuk JY, An JJ, Cha HH, Choi SJ, Vargas JE, Oh SY, et al. Optimal time interval between a single course of antenatal corticosteroids and delivery for reduction of respiratory distress syndrome in preterm twins. Am J Obstet Gynecol. 2013;209(3):256.e1–7. Epub 2013-09-01. pmid:23810815.
- 26. Gulersen M, Gyamfi-Bannerman C, Greenman M, Lenchner E, Rochelson B, Bornstein E. Time interval from late preterm antenatal corticosteroid administration to delivery and the impact on neonatal outcomes. Am J Obstet Gynecol MFM. 2021;3(5):100426. Epub 2021-09-01. pmid:34153514.
- 27. Norman M, Piedvache A, Borch K, Huusom LD, Bonamy AE, Howell EA, et al. Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort. Jama Pediatr. 2017;171(7):678–686. Epub 2017-07-01. pmid:28505223.
- 28. Sakurai K, Takeba Y, Osada Y, Mizuno M, Tsuzuki Y, Aso K, et al. Antenatal Glucocorticoid Administration Promotes Cardiac Structure and Energy Metabolism Maturation in Preterm Fetuses. Int J Mol Sci. 2022;23(17). Epub 2022-09-05. pmid:36077580.
- 29. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367(26):2515–26. Epub 2012-12-27. pmid:23268666.
- 30. Ryu J. New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics. Int J Mol Sci. 2022;23(15). Epub 2022-08-01. pmid:35955664.
- 31. Maini B, Chellani H, Arya S, Guliani BP. Retinopathy of prematurity: risk factors and role of antenatal betamethasone in Indian preterm newborn babies. J Clin Neonatol. 2014;3(1):20–4. Epub 2014-01-01. pmid:24741536.
- 32. Higgins RD, Mendelsohn AL, DeFeo MJ, Ucsel R, Hendricks-Munoz KD. Antenatal dexamethasone and decreased severity of retinopathy of prematurity. Arch Ophthalmol. 1998;116(5):601–5. Epub 1998-05-01. pmid:9596495.
- 33. Zeng Y, Ge G, Lei C, Zhang M. Beyond Fetal Immunity: A Systematic Review and Meta-Analysis of the Association Between Antenatal Corticosteroids and Retinopathy of Prematurity. Front Pharmacol. 2022;13:759742. Epub 2022-01-20. pmid:35153772.
- 34. Melamed N, Shah J, Soraisham A, Yoon EW, Lee SK, Shah PS, et al. Association Between Antenatal Corticosteroid Administration-to-Birth Interval and Outcomes of Preterm Neonates. Obstet Gynecol. 2015;125(6):1377–1384. Epub 2015-06-01. pmid:26000509.
- 35. Karmoker RK, Mirza TT, Hossain AK, Ali MA, Sarker K, Zaman K, et al. Influence of the Interval between Antenatal Corticosteroid Therapy and Delivery on the Incidence of Respiratory Distress Syndrome in Neonate. Mymensingh Med J. 2020;29(1):60–65. Epub 2020-01-01. pmid:31915337.
- 36. Ring AM, Garland JS, Stafeil BR, Carr MH, Peckman GS, Pircon RA. The effect of a prolonged time interval between antenatal corticosteroid administration and delivery on outcomes in preterm neonates: a cohort study. Am J Obstet Gynecol. 2007;196(5):457.e1–6. Epub 2007-05-01. pmid:17466700.